D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
Related Stories
Hospitals protest as Eli Lilly withholds 340B drug discounts nationwide / 4 wks
Tampa General sues Eli Lilly over pulled 340B discounts / 14 days
Eli Lilly demands 340B claims data or cuts hospitals off / 7 wks
340B discounts face reform as profits outpace patient benefit / 3 months
AbbVie sues HHS over 340B patient definition and guidance / 3 months
Hospitals push regulators to block expanded 340B claims reporting requirements / 4 months
CVS sues Tennessee over PBM‑pharmacy separation law / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Novo Nordisk, Drug Pricing, Supply Chain and look for the RSS link.
StackHealth Time Machine